Scarica l'app Stockscreener
74.19
2.85%
-2.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Nektar Therapeutics Borsa (NKTR) Ultime notizie
How Investors Are Reacting To Nektar Therapeutics (NKTR) Q2 Loss, ESOP Shelf Registration And Financing Flexibility - simplywall.st
JPMorgan Chase & Co. Initiates Coverage on Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect - ACCESS Newswire
Nektar Therapeutics chief R&D officer Zalevsky sells $13,388 in shares - Investing.com
Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock By Investing.com - Investing.com South Africa
Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 186 Shares of Stock - MarketBeat
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $30,087.64 in Stock - MarketBeat
Nektar (NKTR) Q2 2026 Earnings Call Transcript - AOL.com
Nektar Therapeutics Stock Historical Valuations | XTER:ITH0 - GuruFocus
Nektar Therapeutics (NKTR) exec sells shares only to cover taxes - Stock Titan
Nektar Therapeutics Stock Operating Data - GuruFocus
NKTR Stock Quote Price and Forecast - CNN
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar Therapeutics (XTER:ITH0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Nektar Therapeutics (XTER:ITH0) Stock News, Headlines & Updates - GuruFocus
Nektar Therapeutics (XTER:ITH0) Stock Price, Trades & News - GuruFocus
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets - Moomoo
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Nektar (NASDAQ: NKTR) exec to sell 186 shares, partly for taxes - Stock Titan
Nektar Therapeutics (NASDAQ: NKTR) insider plans 418-share sale - Stock Titan
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation | NDAQ:NKTR | Press Release - Stockhouse
Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress - simplywall.st
Piper Sandler Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR) - The Globe and Mail
NKTR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise - Yahoo Finance
Two Seas Capital group (NKTR) reports 9.1% Nektar Therapeutics ownership via investment funds - Stock Titan
Biotechnology Value Fund group (NKTR) discloses 7.1% beneficial stake in Nektar - Stock Titan
Is Nektar Therapeutics (NKTR) Still Below Fair Value After Its Recent Run Up? - Sahm
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming (NKTR) - Seeking Alpha
Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch - Yahoo Finance
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus - TradingView
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $192 - Moomoo
Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)? - simplywall.st
Boost Run, Nektar Therapeutics, Swarmer - TradingView
Nektar Therapeutics Q2 2026 Earnings Call Summary - Yahoo Finance
Nektar Therapeutics Boosts Cash to Over $1 Billion After Major Dilutive Equity Raises - Minichart
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - Moomoo
NEKTAR THERAPEUTICS Q2 2026: Revenue $10.1M, EPS $(1.23) — 10-Q Summary - TradingView
Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss - Stock Titan
Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: Respeg Phase 3 Momentum and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics Cash Reaches $1.02 Billion After $373.8 Million Offering - Minichart
Nektar Therapeutics rated Strong Buy on REZPEG's promising Phase 3 trials for atopic dermatitis and alopecia areata. - Pluang
Nektar Raises Cash to Fund Rezpegaldesleukin Phase 3 Trials Through 2028 - The Clinical Trial Vanguard
Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: R - GuruFocus
Nektar Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Nektar beats Q2 2026 EPS but stock slips after hours - Investing.com Nigeria
Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call - Benzinga
Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS - MarketBeat
Nektar Therapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Is Nektar Therapeutics (NKTR) Oversold After Q2 Earnings Miss? G - GuruFocus
Nektar Therapeutics posts Q2 2026 net loss $40.6M; cash and investments $1.023B - TradingView
Nektar Therapeutics Q2 Loss Narrows, Revenue Declines - marketscreener.com
Nektar: Q2 Earnings Snapshot - kare11.com
NEKTAR THERAPEUTICS ($NKTR) Releases Q2 2026 Earnings - Quiver Quantitative
Nektar Therapeutics Q2 revenue falls, net loss narrows - TradingView
Earnings Flash (NKTR) Nektar Therapeutics Posts Q2 Loss $1.23 Per Share, vs. FactSet Est of $1.97 Loss - marketscreener.com
Nektar Therapeutics Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):